CorMedix's Heron Asset Buy Adds Four Marketed Drugs and About $150M in Revenue

What happened

CorMedix Inc. has agreed to buy substantially all of Heron Therapeutics' assets. The deal brings four marketed products under one roof: ZYNRELEF, APONVIE, CINVANTI and SUSTOL. The portfolio generated about $150 million in trailing-12-month net revenue, and a Pharmakon term loan backs the purchase.

The structure is an asset purchase rather than a merger of companies, so CorMedix is taking the products and operations it wants. The material we have does not give a purchase price, a closing timetable or the loan's terms, and those details will shape how the deal is judged.

The strategic logic

The appeal is simple. CorMedix is buying revenue that already exists. About $150 million of trailing net revenue from four marketed brands is a different proposition from a pipeline bet, and it gives the buyer a larger commercial base from day one. Four products also spread risk across a portfolio, so no single brand carries the whole top line.

Assets sold as a package suggest the buyer sees value in the portfolio as a whole. The commercial question is whether CorMedix can run these brands at least as well as Heron did, and whether the combined business shares infrastructure efficiently. Whether it can is analysis, not disclosed fact. The deal's economics will depend on how much of the acquired revenue survives the transition and how much overlap exists between the two sales operations.

Financing: debt rather than dilution

The Pharmakon term loan is a notable feature. Funding a revenue-generating acquisition with a term loan is a common way to avoid issuing equity, and it matches a purchase of assets that already produce cash. The trade-off is fixed obligations. Debt service will sit against the acquired revenue, so the stability of that revenue matters more than it would in an equity-funded deal.

Without the loan's size, pricing and covenants, we cannot say how much headroom the combined company has. Those terms are among the first things to check when documents are filed.

Context: how the rest of the market is trading assets

Other news this week shows how varied the deal landscape is, and how unlike the CorMedix transaction most of it is.

At the small-biotech end, deals are modest or defensive. Theriva Biologics sold its SYN-004 antibiotic-enzyme assets to Biossil Labs for $350,000 upfront. Longeveron is starting a strategic alternatives review, weighing a sale or merger, after laromestrocel missed its primary endpoint in the ELPIS II trial in infants with hypoplastic left heart syndrome. MacroGenics reports $288 million in cash and a runway into 2028, and says non-dilutive deals, including a manufacturing sale and a ZYNYZ royalty sale, help fund its focus on the investigational ADC MGC026.

Others are building. Kiora has licensed rights outside Asia to Senju's oral calpain inhibitor KIO-401 (mitucapistat) for retinal artery occlusion and has asked the FDA for a pre-IND meeting and orphan drug designation. Xenetic is advancing an all-stock acquisition of Santersus, targeting a Q1 2027 close. Silence Therapeutics, with $247.7 million in cash and positive Phase 2 divesiran data in polycythemia vera, faces a pending acquisition by Merck KGaA.

Read together, capital is available for assets with revenue or clear late-stage data, while earlier or failed programs are being sold, licensed or put up for strategic review. CorMedix is buying the former. Heron's decision to sell substantially all of its assets, and the tone of the small-cap divestments, point to a market that rewards commercial scale.

Risks

Integration is the main risk. Four marketed products mean transferring contracts, supply arrangements and commercial teams, and any disruption could erode the $150 million revenue base the financing relies on. That figure is a trailing number, and the material does not say whether it is growing, flat or declining.

Leverage is the second. A term loan lowers dilution but adds fixed costs, which makes execution more important. The third is deal certainty: an asset sale of this scope will need to close, and the material gives no timeline or conditions. The CMA's Phase 1 findings on AkzoNobel-Axalta, though in a different industry, are a reminder that regulators scrutinise overlaps narrowly and that agreed divestments can resolve them. The material gives no sign of such issues here, and we do not suggest any.

What to watch

Watch for the purchase price and closing conditions, the full terms of the Pharmakon loan, and the first combined revenue figures after closing. Also watch how CorMedix describes the split between the four brands, and whether it sets out synergies or cost targets. Elsewhere, Longeveron's strategic review and Xenetic's Q1 2027 close will show whether small-cap consolidation picks up.